Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1997 Nov;71(11):8615–8623. doi: 10.1128/jvi.71.11.8615-8623.1997

Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.

H Cao 1, P Kanki 1, J L Sankalé 1, A Dieng-Sarr 1, G P Mazzara 1, S A Kalams 1, B Korber 1, S Mboup 1, B D Walker 1
PMCID: PMC192325  PMID: 9343219

Abstract

Despite recent advances in antiviral therapy for human immunodeficiency virus (HIV) infection, successful global intervention will require an effective vaccine. Expanding evidence suggests that cytotoxic T-lymphocyte (CTL) responses will be an important component of such a vaccine. The varying geographic distribution of HIV type 1 (HIV-1) clades, with the relative absence of clade B HIV-1 outside the developed world, is considered a major obstacle to the development of a single efficacious vaccine. An understanding of cross-reactive CTL responses between different HIV-1 clades is crucial in the design of a vaccine which will be broadly immunogenic. In this study, we examined the ability of HIV-1 Gag-, reverse transcriptase-, and Env-specific CTL clones isolated from individuals infected in the United States to recognize non-B clade viral sequences and found that all were cross-reactive with the majority of non-B clade viral sequences tested. We next studied HIV-1-specific CTL responses in African individuals infected with clade A, C, or G virus and evaluated cross-recognition of clade B virus. Of 14 persons evaluated, all demonstrated cross-reactivity with the U.S. clade B viral constructs. We conclude that significant CTL cross-reactivity exists between clade B and non-B epitopes, suggesting that CTL cross-recognition among HIV-1 clades is more widespread than anticipated and that a vaccine based on a single clade may be broadly applicable.

Full Text

The Full Text of this article is available as a PDF (1.4 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allsopp C. E., Harding R. M., Taylor C., Bunce M., Kwiatkowski D., Anstey N., Brewster D., McMichael A. J., Greenwood B. M., Hill A. V. Interethnic genetic differentiation in Africa: HLA class I antigens in The Gambia. Am J Hum Genet. 1992 Feb;50(2):411–421. [PMC free article] [PubMed] [Google Scholar]
  2. Bergmann C. C., Yao Q., Ho C. K., Buckwold S. L. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J Immunol. 1996 Oct 15;157(8):3242–3249. [PubMed] [Google Scholar]
  3. Borrow P., Lewicki H., Hahn B. H., Shaw G. M., Oldstone M. B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994 Sep;68(9):6103–6110. doi: 10.1128/jvi.68.9.6103-6110.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Borrow P., Lewicki H., Wei X., Horwitz M. S., Peffer N., Meyers H., Nelson J. A., Gairin J. E., Hahn B. H., Oldstone M. B. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997 Feb;3(2):205–211. doi: 10.1038/nm0297-205. [DOI] [PubMed] [Google Scholar]
  5. Byrne J. A., Oldstone M. B. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J Virol. 1984 Sep;51(3):682–686. doi: 10.1128/jvi.51.3.682-686.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carr J. K., Salminen M. O., Koch C., Gotte D., Artenstein A. W., Hegerich P. A., St Louis D., Burke D. S., McCutchan F. E. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol. 1996 Sep;70(9):5935–5943. doi: 10.1128/jvi.70.9.5935-5943.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cease K. B., Berzofsky J. A. Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development. Annu Rev Immunol. 1994;12:923–989. doi: 10.1146/annurev.iy.12.040194.004423. [DOI] [PubMed] [Google Scholar]
  8. Collier A. C., Coombs R. W., Schoenfeld D. A., Bassett R. L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V. J. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996 Apr 18;334(16):1011–1017. doi: 10.1056/NEJM199604183341602. [DOI] [PubMed] [Google Scholar]
  9. Del Val M., Schlicht H. J., Ruppert T., Reddehase M. J., Koszinowski U. H. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell. 1991 Sep 20;66(6):1145–1153. doi: 10.1016/0092-8674(91)90037-y. [DOI] [PubMed] [Google Scholar]
  10. Dolin R. Human studies in the development of human immunodeficiency virus vaccines. J Infect Dis. 1995 Nov;172(5):1175–1183. doi: 10.1093/infdis/172.5.1175. [DOI] [PubMed] [Google Scholar]
  11. Earl P. L., Koenig S., Moss B. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J Virol. 1991 Jan;65(1):31–41. doi: 10.1128/jvi.65.1.31-41.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Esparza J., Osmanov S., Heyward W. L. HIV preventive vaccines. Progress to date. Drugs. 1995 Nov;50(5):792–804. doi: 10.2165/00003495-199550050-00003. [DOI] [PubMed] [Google Scholar]
  13. Ferrari G., Humphrey W., McElrath M. J., Excler J. L., Duliege A. M., Clements M. L., Corey L. C., Bolognesi D. P., Weinhold K. J. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1396–1401. doi: 10.1073/pnas.94.4.1396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gao F., Robertson D. L., Morrison S. G., Hui H., Craig S., Decker J., Fultz P. N., Girard M., Shaw G. M., Hahn B. H. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol. 1996 Oct;70(10):7013–7029. doi: 10.1128/jvi.70.10.7013-7029.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Graham B. S., Wright P. F. Candidate AIDS vaccines. N Engl J Med. 1995 Nov 16;333(20):1331–1339. doi: 10.1056/NEJM199511163332007. [DOI] [PubMed] [Google Scholar]
  16. Gritz L., Destree A., Cormier N., Day E., Stallard V., Caiazzo T., Mazzara G., Panicali D. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J Virol. 1990 Dec;64(12):5948–5957. doi: 10.1128/jvi.64.12.5948-5957.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Harrer E., Harrer T., Buchbinder S., Mann D. L., Feinberg M., Yilma T., Johnson R. P., Walker B. D. HIV-1-specific cytotoxic T lymphocyte response in healthy, long-term nonprogressing seropositive persons. AIDS Res Hum Retroviruses. 1994;10 (Suppl 2):S77–S78. [PubMed] [Google Scholar]
  18. Harrer T., Harrer E., Kalams S. A., Barbosa P., Trocha A., Johnson R. P., Elbeik T., Feinberg M. B., Buchbinder S. P., Walker B. D. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol. 1996 Apr 1;156(7):2616–2623. [PubMed] [Google Scholar]
  19. Harrer T., Harrer E., Kalams S. A., Elbeik T., Staprans S. I., Feinberg M. B., Cao Y., Ho D. D., Yilma T., Caliendo A. M. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses. 1996 May 1;12(7):585–592. doi: 10.1089/aid.1996.12.585. [DOI] [PubMed] [Google Scholar]
  20. Haynes B. F. HIV vaccines: where we are and where we are going. Lancet. 1996 Oct 5;348(9032):933–937. doi: 10.1016/S0140-6736(96)09339-7. [DOI] [PubMed] [Google Scholar]
  21. Haynes B. F., Pantaleo G., Fauci A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996 Jan 19;271(5247):324–328. doi: 10.1126/science.271.5247.324. [DOI] [PubMed] [Google Scholar]
  22. Heslop H. E., Ng C. Y., Li C., Smith C. A., Loftin S. K., Krance R. A., Brenner M. K., Rooney C. M. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996 May;2(5):551–555. doi: 10.1038/nm0596-551. [DOI] [PubMed] [Google Scholar]
  23. Jassoy C., Johnson R. P., Navia B. A., Worth J., Walker B. D. Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex. J Immunol. 1992 Nov 1;149(9):3113–3119. [PubMed] [Google Scholar]
  24. Johnson R. P., Trocha A., Buchanan T. M., Walker B. D. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J Exp Med. 1992 Apr 1;175(4):961–971. doi: 10.1084/jem.175.4.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Johnson R. P., Trocha A., Yang L., Mazzara G. P., Panicali D. L., Buchanan T. M., Walker B. D. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol. 1991 Sep 1;147(5):1512–1521. [PubMed] [Google Scholar]
  26. Kalams S. A., Johnson R. P., Dynan M. J., Hartman K. E., Harrer T., Harrer E., Trocha A. K., Blattner W. A., Buchbinder S. P., Walker B. D. T cell receptor usage and fine specificity of human immunodeficiency virus 1-specific cytotoxic T lymphocyte clones: analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant. J Exp Med. 1996 Apr 1;183(4):1669–1679. doi: 10.1084/jem.183.4.1669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kanki P., M'Boup S., Marlink R., Travers K., Hsieh C. C., Gueye A., Boye C., Sankalé J. L., Donnelly C., Leisenring W. Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) and human immunodeficiency virus type 1 (HIV-1) in west African female prostitutes. Am J Epidemiol. 1992 Oct 1;136(7):895–907. doi: 10.1093/aje/136.7.895. [DOI] [PubMed] [Google Scholar]
  28. Klein M. R., van Baalen C. A., Holwerda A. M., Kerkhof Garde S. R., Bende R. J., Keet I. P., Eeftinck-Schattenkerk J. K., Osterhaus A. D., Schuitemaker H., Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med. 1995 Apr 1;181(4):1365–1372. doi: 10.1084/jem.181.4.1365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994 Jul;68(7):4650–4655. doi: 10.1128/jvi.68.7.4650-4655.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Koup R. A., Sullivan J. L., Levine P. H., Brewster F., Mahr A., Mazzara G., McKenzie S., Panicali D. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol. 1989 Feb;63(2):584–590. doi: 10.1128/jvi.63.2.584-590.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Langlade-Demoyen P., Ngo-Giang-Huong N., Ferchal F., Oksenhendler E. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J Clin Invest. 1994 Mar;93(3):1293–1297. doi: 10.1172/JCI117085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Letvin N. L. Vaccines against human immunodeficiency virus--progress and prospects. N Engl J Med. 1993 Nov 4;329(19):1400–1405. doi: 10.1056/NEJM199311043291908. [DOI] [PubMed] [Google Scholar]
  33. Lubaki M. N., Egan M. A., Siliciano R. F., Weinhold K. J., Bollinger R. C. A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res Hum Retroviruses. 1994 Nov;10(11):1427–1431. doi: 10.1089/aid.1994.10.1427. [DOI] [PubMed] [Google Scholar]
  34. Marlink R., Kanki P., Thior I., Travers K., Eisen G., Siby T., Traore I., Hsieh C. C., Dia M. C., Gueye E. H. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994 Sep 9;265(5178):1587–1590. doi: 10.1126/science.7915856. [DOI] [PubMed] [Google Scholar]
  35. Martin R., Utz U., Coligan J. E., Richert J. R., Flerlage M., Robinson E., Stone R., Biddison W. E., McFarlin D. E., McFarland H. F. Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol. 1992 Mar 1;148(5):1359–1366. [PubMed] [Google Scholar]
  36. Neisig A., Roelse J., Sijts A. J., Ossendorp F., Feltkamp M. C., Kast W. M., Melief C. J., Neefjes J. J. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J Immunol. 1995 Feb 1;154(3):1273–1279. [PubMed] [Google Scholar]
  37. Nikolić-Zugić J., Carbone F. R. Peptide presentation by class-I major histocompatibility complex molecules. Immunol Res. 1991;10(1):54–65. doi: 10.1007/BF02918167. [DOI] [PubMed] [Google Scholar]
  38. Over Mead, Piot Peter. Human immunodeficiency virus infection and other sexually transmitted diseases in developing countries: public health importance and priorities for resource allocation. J Infect Dis. 1996 Oct;174(Suppl 2):S162–S175. doi: 10.1093/infdis/174.supplement_2.s162. [DOI] [PubMed] [Google Scholar]
  39. Pinto L. A., Sullivan J., Berzofsky J. A., Clerici M., Kessler H. A., Landay A. L., Shearer G. M. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest. 1995 Aug;96(2):867–876. doi: 10.1172/JCI118133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Reddehase M. J., Mutter W., Münch K., Bühring H. J., Koszinowski U. H. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol. 1987 Oct;61(10):3102–3108. doi: 10.1128/jvi.61.10.3102-3108.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Reddehase M. J., Weiland F., Münch K., Jonjic S., Lüske A., Koszinowski U. H. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol. 1985 Aug;55(2):264–273. doi: 10.1128/jvi.55.2.264-273.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Rinaldo C., Huang X. L., Fan Z. F., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cottrill M. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol. 1995 Sep;69(9):5838–5842. doi: 10.1128/jvi.69.9.5838-5842.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Rowland-Jones S., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., Whitby D., Sabally S., Gallimore A., Corrah T. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995 Jan;1(1):59–64. doi: 10.1038/nm0195-59. [DOI] [PubMed] [Google Scholar]
  44. Sethi K. K., Omata Y., Schneweis K. E. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes. J Gen Virol. 1983 Feb;64(Pt 2):443–447. doi: 10.1099/0022-1317-64-2-443. [DOI] [PubMed] [Google Scholar]
  45. Smith K. A., Stallard V., Roos J. M., Hart C., Cormier N., Cohen L. K., Roberts B. E., Payne L. G. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences. Vaccine. 1993;11(1):43–53. doi: 10.1016/0264-410x(93)90338-x. [DOI] [PubMed] [Google Scholar]
  46. Tsomides T. J., Aldovini A., Johnson R. P., Walker B. D., Young R. A., Eisen H. N. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med. 1994 Oct 1;180(4):1283–1293. doi: 10.1084/jem.180.4.1283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Tsomides T. J., Walker B. D., Eisen H. N. An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11276–11280. doi: 10.1073/pnas.88.24.11276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Walker B. D., Chakrabarti S., Moss B., Paradis T. J., Flynn T., Durno A. G., Blumberg R. S., Kaplan J. C., Hirsch M. S., Schooley R. T. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987 Jul 23;328(6128):345–348. doi: 10.1038/328345a0. [DOI] [PubMed] [Google Scholar]
  49. Walker B. D., Flexner C., Birch-Limberger K., Fisher L., Paradis T. J., Aldovini A., Young R., Moss B., Schooley R. T. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9514–9518. doi: 10.1073/pnas.86.23.9514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Walker B. D., Flexner C., Paradis T. J., Fuller T. C., Hirsch M. S., Schooley R. T., Moss B. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science. 1988 Apr 1;240(4848):64–66. doi: 10.1126/science.2451288. [DOI] [PubMed] [Google Scholar]
  51. Walter E. A., Greenberg P. D., Gilbert M. J., Finch R. J., Watanabe K. S., Thomas E. D., Riddell S. R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995 Oct 19;333(16):1038–1044. doi: 10.1056/NEJM199510193331603. [DOI] [PubMed] [Google Scholar]
  52. Wilson C. C., Wong J. T., Girard D. D., Merrill D. P., Dynan M., An D. D., Kalams S. A., Johnson R. P., Hirsch M. S., D'Aquila R. T. Ex vivo expansion of CD4 lymphocytes from human immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral agents. J Infect Dis. 1995 Jul;172(1):88–96. doi: 10.1093/infdis/172.1.88. [DOI] [PubMed] [Google Scholar]
  53. Wolinsky S. M., Wike C. M., Korber B. T., Hutto C., Parks W. P., Rosenblum L. L., Kunstman K. J., Furtado M. R., Muñoz J. L. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science. 1992 Feb 28;255(5048):1134–1137. doi: 10.1126/science.1546316. [DOI] [PubMed] [Google Scholar]
  54. Wong J. T., Colvin R. B. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol. 1987 Aug 15;139(4):1369–1374. [PubMed] [Google Scholar]
  55. Yap K. L., Ada G. L., McKenzie I. F. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature. 1978 May 18;273(5659):238–239. doi: 10.1038/273238a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES